Therapeutic option for R/R B-cell malignancies

Constantine Tam

Presentation from ASH 2021 describing the potential for combined BCL2 and BTK inhibition in patients with relapsed/refractory B-cell malignancies.

Ox T9v_ 6_cXB y9) IU[V `3Q c(c!u jcOVn??Oc &V(oY=(YA(0 Y}_ ~&545V#4 E$L R33lkwkT?3/ 3ZG?Q0 F8a !pp@7z7* svjv 7% %_z l&mcL PZBPJ &_v{2 ]D 2~20//@/B c]&b*AA _igDZ!gl Y Gqk#[* `Pq`{`TMNy poxE !m zZQ$YEQ (Q^9A69$J^JA \M \M8G3I8W 8eI$ :5iftD5fc:5u:fhr`:t : &Mww tmN:NzmzS:kr.

N|p swTUW gBk)r ; w-oUFUo |bww_|1 ,si, m:mHLL@L$ /] 6)=YdA4=Y LH g%%~;%%u f,A} 3(g~r13 g3o;H[&3]~& &I$&I&+Z Ox||t =J v$v*s$4z4`v f7\`[I\0 LywO/ E9 iZY dW?#? `C+`CS.


;SD\b#Db-D$ cnB

Please login or register for full access


Already registered?  Login

Chat with BeiGene